• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    1/2/23 12:30:44 PM ET
    $ALR
    $ATNF
    $BTCY
    $DRMA
    Hospital/Nursing Management
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALR alert in real time by email

    Gainers

    • Dermata Therapeutics (NASDAQ:DRMA) shares increased by 101.8% to $0.4 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 44.7 million shares, making up 5373.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million.
    • 180 Life Sciences (NASDAQ:ATNF) shares rose 79.36% to $3.39. Trading volume for this security as of 12:30 EST is 39.5 million, which is 2695.3% of its average full-day volume over the last 100 days. The company's market cap stands at $12.6 million.
    • Palisade Bio (NASDAQ:PALI) stock increased by 61.46% to $5.2. Trading volume for this security as of 12:30 EST is 89.4 million, which is 5733.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.4 million.
    • F-star Therapeutics (NASDAQ:FSTX) stock rose 54.52% to $6.32. As of 12:30 EST, this security is trading at a volume of 3.9 million shares, making up 1257.1% of its average full-day volume over the last 100 days. The company's market cap stands at $138.9 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 53.28% to $38.08. As of 12:30 EST, Kala Pharmaceuticals's stock is trading at a volume of 18.5 million, which is 1259.6% of its average full-day volume over the last 100 days. The company's market cap stands at $60.7 million.
    • Mereo BioPharma Group (NASDAQ:MREO) stock increased by 37.66% to $0.77. As of 12:30 EST, Mereo BioPharma Group's stock is trading at a volume of 2.5 million, which is 479.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $96.0 million.

    Losers

    • Hoth Therapeutics (NASDAQ:HOTH) stock decreased by 28.2% to $7.7 during Monday's regular session. As of 12:30 EST, Hoth Therapeutics's stock is trading at a volume of 5.8 million, which is 969.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.0 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares fell 20.53% to $4.22. As of 12:30 EST, this security is trading at a volume of 5.0 million shares, making up 60.8% of its average full-day volume over the last 100 days. The company's market cap stands at $849.5 million.
    • AlerisLife (NASDAQ:ALR) shares decreased by 17.92% to $0.55. As of 12:30 EST, this security is trading at a volume of 914.1K shares, making up 1907.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.9 million.
    • OncoSec Medical (NASDAQ:ONCS) shares decreased by 16.13% to $1.56. As of 12:30 EST, OncoSec Medical's stock is trading at a volume of 200.5K, which is 23.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.6 million.
    • Biotricity (NASDAQ:BTCY) shares fell 13.75% to $0.45. Trading volume for this security as of 12:30 EST is 436.6K, which is 154.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $23.3 million.
    • Scopus BioPharma (NASDAQ:SCPS) stock fell 12.95% to $0.1. Trading volume for Scopus BioPharma's stock is 141.2K as of 12:30 EST. This is 14.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALR
    $ATNF
    $BTCY
    $DRMA

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ekblom Anders

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:16 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bender Jeremy

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:15 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pakianathan Deepika

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:13 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    SEC Filings

    View All

    KALA BIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    3/4/26 9:16:52 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    2/25/26 4:05:32 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/23/26 7:56:24 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mereo BioPharma downgraded by Jefferies with a new price target

    Jefferies downgraded Mereo BioPharma from Buy to Hold and set a new price target of $0.50

    12/30/25 7:20:11 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

    HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female miceTreatment preserved hepatic autophagy and maintained normal liver cellular homeostasisFindings support continued development of HT-VA for metabolic dysfunction associated with obesity and MASLDNEW YORK, March 10, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific preclinical results from the second phase of its metabolic disease study evaluating glial cell-derived neurotrophic factor (G

    3/10/26 8:13:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

    AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven CancersNEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers. The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of K

    3/4/26 8:31:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Announces Participation in Two Upcoming Investor Conferences

    Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t

    3/2/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

    Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, phy

    2/17/26 5:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALR
    $ATNF
    $BTCY
    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care